BiQadx
Assay DevelopmentQ4 2025 · 9 min read

Lyophilized Reagent Stability in Extreme Environments

Freeze-dried reagent beads are the linchpin of room-temperature stable POCT cartridges. This study quantifies the thermal degradation kinetics of our proprietary lyophilised enzyme-antibody conjugates across a 10–95% RH gradient and three accelerated temperature regimes, establishing a validated 24-month shelf-life model.

BQ
BiQadx Core Engineering
Q4 2025
9 min read
24 mo
Validated Shelf Life
At 2–8°C sealed pouch
<1%
Residual Moisture
Target w/w post-lyophilisation
97.4%
Activity Retention
After 6mo at 40°C/75%RH
◆ Engineering Process Flow
1
FORMULATE
2
LYOPHILIZE
3
VALIDATE
4
STABILITY
5
CERTIFY
◆ Key Findings
  • Tg' of −28.4°C enabled a 7°C safety margin during primary drying — zero cake collapse events across 12 production lots
  • Arrhenius modelling predicts 98.1% activity retention at 24 months (2–8°C) — confirmed by ongoing real-time study at Month 12
  • UN3373 ambient transport specification validated: ≤72h at ≤55°C causes <15% LOD shift — cold-chain not required for short-haul distribution
01

Lyophilisation Science & Collapse Temperature

The glass transition temperature (Tg') of our formulation — a trehalose/sucrose/mannitol cryoprotectant matrix — was determined by modulated DSC (TA Instruments Q2000) at −28.4°C. Primary drying was conducted at −35°C shelf temperature under 100 mTorr chamber pressure, maintaining a 7°C safety margin below Tg' to prevent cake collapse. Secondary drying ramped to +25°C at 0.1°C/min to desorb bound water without denature the antibody Fc region. Final residual moisture by Karl Fischer titration: 0.71±0.09% w/w across 12 production lots.

02

Accelerated Degradation Study — ICH Q1A Protocol

Following ICH Q1A(R2) accelerated stability guidelines, three conditions were evaluated: 25°C/60%RH (intermediate), 40°C/75%RH (accelerated), and 60°C/ambient (stress). Arrhenius kinetic modelling using the derived activation energy (Ea = 84.3 kJ/mol for the conjugate's GOx enzymatic activity) extrapolates a degradation rate constant k25 = 0.0014 month⁻¹ at 25°C. This predicts >97% activity retention at 24 months under real-time conditions. At 40°C, the predicted shelf life is 6.8 months — concordant with observed 97.4% retention at 6 months in the accelerated study.

03

Humidity Sensitivity & Packaging Specification

Exposure to humidity above 40%RH in unwrapped beads caused measurable activity loss within 4 hours, confirming that container closure integrity is the critical control point. Our tri-layer foil pouch (PET/Al/PE, WVTR <0.001 g/m²/day at 38°C/90%RH per ASTM F1249) with 1g molecular sieve desiccant maintains internal RH≤15% for the 24-month product life. Acceptance criteria for incoming pouches: residual oxygen headspace <0.5% (measured by Mocon OxTran 2/22).

04

Field Thermal Excursion Study

A simulated 'truck transport in Gulf climate' scenario exposed sealed pouches to 55°C for 72 hours (equivalent to 6.3 months at 40°C using the Q10 rule with Q10=2.6). Post-excursion assay performance: LOD shift <15%, CV change <2 percentage points, calibration curve slope shift <5%. These results underpin BiQadx's UN3373 transport specification, allowing shipment without cold-chain for durations <72 hours below 55°C.

Accelerated Stability Data — Enzyme Activity Retention (%)
Time Point2–8°C25°C/60%RH40°C/75%RH60°C Stress
T=0 (Baseline)100.0%100.0%100.0%100.0%
1 Month99.8%99.5%98.7%94.2%
3 Months99.6%99.0%97.4%81.3%
6 Months99.3%98.3%94.1%61.7%
12 Months98.8%96.9%
24 Months (real-time)98.1%
Activity measured by substrate turnover rate (OD/min) at 450nm. n=6 replicates per condition per time point. Acceptance: ≥90% retention.BiQadx Engineering Data

Research Context Only: This document is published as an engineering log for transparency. All content describes R&D-phase investigations. No clinical diagnostic claims are made. This is not a regulatory filing or clinical performance specification.

Engineering LibraryINS-004 / BiQadx © 2026
BiQadx content is R&D / prototype / pilot-stage. No clinical claims. For planning and technical understanding only. Not medical advice.